Lantern Pharma (NASDAQ: LTRN), a clinical-stage AI-driven precision oncology company, announced that it will report its first-quarter 2026 operating and financial results via press release on May 15. The update will include financial results for the quarter ended March 31, 2026, along with operational updates regarding the company’s clinical trials and development of its proprietary artificial intelligence and machine learning platforms. The announcement underscores the company's ongoing efforts to leverage its AI capabilities to accelerate cancer therapy development.
Lantern’s clinical pipeline includes LP-184 (acylfulvene), LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300 (cisplatin/ethacraplatin analog), which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. These programs reflect the company's focus on precision oncology and targeted therapies.
In addition to its pipeline, Lantern has made strides in commercializing its AI platforms. withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform for the global biomedical and drug development community, representing a new revenue stream for the Company. This development could position Lantern as a key player in the AI-driven drug discovery space, potentially diversifying its revenue beyond traditional biotech funding. The company also operates an AI Center of Excellence in Bengaluru, India and is headquartered in Dallas, Texas.
For more details on the announcement, the full press release is available at https://ibn.fm/dVleQ. Investors seeking additional updates on LTRN can visit the company’s newsroom at https://ibn.fm/LTRN. The upcoming report will be closely watched by investors and analysts interested in the progress of Lantern's clinical trials and the adoption of its AI platforms.
